UK markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.09-1.06 (-2.20%)
At close: 04:00PM EDT
47.09 0.00 (0.00%)
After hours: 07:02PM EDT

Beam Therapeutics Inc.

238 Main Street
9th Floor
Cambridge, MA 02142
United States
857 327 8775
https://www.beamtx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees476

Key executives

NameTitlePayExercisedYear born
Mr. John M. Evans M.B.A.CEO & Director1.02M1.62M1978
Dr. Giuseppe Ciaramella Ph.D.Pres & Chief Scientific Officer890.79k14.85M1969
Ms. Terry-Ann Burrell M.B.A.CFO & Treasurer687.52k9.18M1977
Dr. Feng Zhang Ph.D.Co-FounderN/AN/AN/A
Dr. David R. Liu Ph.D.Co-FounderN/AN/AN/A
Dr. J. Keith Joung M.D., Ph.D.Co-FounderN/AN/AN/A
Dr. Nicole Gaudelli Ph.D.Co-FounderN/AN/AN/A
Dr. Alexis Komor Ph.D.Co-FounderN/AN/AN/A
Ms. Suzanne FlemingChief Accounting OfficerN/AN/A1961
Mr. Brian RileySr. VP of Technical OperationsN/AN/A1977
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Corporate governance

Beam Therapeutics Inc.’s ISS governance QualityScore as of 1 September 2022 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.